366.F · AzurRx BioPharma, Inc

-

Please sign in to comment on 366.F

1 Comment

Admin

4 years, 1 month ago

AzurRx BioPharma, Inc is currently in a long term downtrend where the price is trading 22.8% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

AzurRx BioPharma, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 1257.7% to $-17M since the same quarter in the previous year.

Finally, its free cash flow fell by 82.2% to $-6M since the same quarter in the previous year.

Based on the above factors, AzurRx BioPharma, Inc gets an overall score of 1/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	F
CurrencyCode	EUR
ISIN	US33749P2002

Market Cap	5M
PE Ratio	None
Target Price	None
Beta	1.51
Dividend Yield	None

ABOUT

AzurRx BioPharma, Inc

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is based in Boca Raton, Florida.

366.F · AzurRx BioPharma, Inc

-

AzurRx BioPharma, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest AzurRx BioPharma, Inc using a moving average strategy